NRIX stock is rated Strong Buy as bexobrutideg advances in CLL trials. See here for NRIX stock's milestones, market potential ...

AstraZeneca (($AZN)) announced an update on their ongoing clinical study. Study Overview: AstraZeneca is conducting a Phase III study titled ‘A ...

Acalabrutinib plus obinutuzumab shows superior long-term outcomes in treatment-naive chronic lymphocytic leukemia.

CLL-related immune dysfunction, along with therapy-associated immunosuppression, contributes to impaired tumor surveillance.

Pirtobrutinib is currently approved for the treatment of patients with CLL/SLL who have received at least 2 prior lines of therapy.

Recent developments in the treatment of chronic lymphocytic leukemia (CLL) have included a fixed-duration oral combination ...

Autism Research EXPERT Says Trump’s TYLENOL Claims ‘EXTREME’ & ‘DEVASTATING’ | SUNRISE The Trump administration is touting an old generic drug as a ...

Please provide your email address to receive an email when new articles are posted on . In this video, Joshua Brody, MD, discusses results from an ongoing phase 1a study of bexobrutideg, a novel ...

Pirtobrutinib was associated with a statistically significant improvement in PFS compared with bendamustine plus rituximab therapy. Topline data were announced from a phase 3 trial evaluating ...

In the Phase 3 BRUIN CLL-313 study, treatment with pirtobrutinib demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival versus bendamustine ...